Pipeline

We’re working with our partners to identify more unmet medical needs and focus our research where it is needed most. Our growing pipeline includes first-in-class therapies aimed at providing new solutions and cancer support where no options currently exist, and helping to lift the burden of cancer for patients.

Clinical Research

We are committed to clinical research with a program of 21 trials from Phase I to III with more than 6,500 patients in 747 centers globally between 2014 and 2016.

 

2015-2017 Research Summary

5,692

Patients Tested

Patients Tested

784

Clinical Centres

Clinical Centres

One Epidemiological Study

Pipeline

Cancer Care
Cancer Therapeutics
Metabolism
Compound Indication Phase
FOSNETUPITANT-PALONOSETRON FIXED COMBINATION IV – EU & countries ex U.S. Chemotherapy-Induced Nausea and Vomiting Regulatory
NETUPITANT-PALONOSETRON FIXED COMBINATION ORAL – CHINA Chemotherapy-Induced Nausea and Vomiting Regulatory
PALONOSETRON IV and ORAL – CHINA Chemotherapy-Induced Nausea and Vomiting Regulatory
PALONOSETRON – CHINA Post-Operative Nausea and Vomiting Phase 3
FOSNETUPITANT IV – JAPAN* Chemotherapy-Induced Nausea and Vomiting Phase 3
ANAMORELIN – GLOBAL Cancer Anorexia-Cachexia in NSCLC** Patients Phase 3
ANAMORELIN JAPAN*** Cancer Anorexia-Cachexia Phase 3
NETUPITANT-PALONOSETRON FIXED COMBINATION ORAL Chronic Nausea and Vomiting in Cancer Patients Phase 2
NETUPITANT-PALONOSETRON ORAL SUSPENSION Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients Phase 2
ANAMORELIN Cancer-Related Fatigue Phase 2
ANAMORELIN – CHINA Cancer Anorexia-Cachexia in NSCLC** Patients Phase 1
HM03 – GHRELIN RECEPTOR AGONIST 2 Cancer Anorexia-Cachexia Preclinical
* Managed by Helsinn’s partner in Japan: Taiho Pharmaceutical
** NSCLC (Non-Small Cell Lung Cancer)
*** Managed by Helsinn’s partner in Japan: Ono Pharmaceutical
**** Managed by MEI Pharma on behalf of Helsinn
***** Co-development with Taiho Pharmaceutical
Compound Indication Phase
PRACINOSTAT Acute Myeloid Leukemia (AML) Phase 3
PRACINOSTAT**** High Risk Myelodysplastic Syndromes (MDS) Phase 2
HM06 – RET INHIBITOR***** Solid Tumors with RET Mutations Preclinical
* Managed by Helsinn’s partner in Japan: Taiho Pharmaceutical
** NSCLC (Non-Small Cell Lung Cancer)
*** Managed by Helsinn’s partner in Japan: Ono Pharmaceutical
**** Managed by MEI Pharma on behalf of Helsinn
***** Co-development with Taiho Pharmaceutical
Compound Indication Phase
HM04 – GHRELIN RECEPTOR ANTAGONIST Prader-Willi Syndrome Phase I
GHRELIN RECEPTOR INVERSE AGONISTS Obesity Research